Relying on a global network of scientific advisors and collaborators, Cardio Polymers has developed extensive domain knowledge and expertise to facilitate continued development of innovative curative therapies directed at congestive heart failure and arrhythmias.
The Company’s research strategy consists of bringing together leading clinical experts in cardiology, heart surgery and electrophysiology along with basic and applied research scientists in biopolymer sciences, computer modeling, tissue engineering and cell therapies. Based on this capital efficient model, the Company is tapping into a growing and exciting range of therapeutic options resulting from an understanding of the biologic mechanisms underlying cardiac disorders. A variety of biopolymers, biologics, growth factors and cells become tools to intervene successfully in the treatment of disease.
In congestive heart failure, Cardio Polymers is currently engaged in two critical areas of research. First, it is developing proprietary bio-specific enhancements to its Algisyl-LVR polymer in order to elicit and accelerate specific responses including tissue regeneration of heart muscle. Second, it is developing alternative delivery tools to facilitate minimally invasive applications for its technology.